| Acceptance rate | 46% |
|---|---|
| Time to first decision | 6 months* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2025 , Vol 63 , Num 3
Development and validation of a versatile ultra performance liquid chromatography method for simultaneous estimation of selected antiviral drugs in bulk and dosage form
1 Department of Pharmaceutical Analysis, Aditya College of Pharmacy, ADB road, Surampalem-533437, India2 Department of Pharmaceutical Analysis, Hindu College of Pharmacy, Amaravathi Road, Guntur-522002, India
DOI : 10.23893/1307-2080.APS6339 Viewed : 27 - Downloaded : 11 This research aimed to develop and validate an accurate Ultra performance Liquid Chromatography (UPLC) method with Photo Diode Array detection to simultaneously estimate Bictegravir, Emtricitabine and Tenofovir Alafenamide Fumarate in their fixed dose combination. The developed method used Acetonitrile and pH 2.5 triethanolamine buffer in a 30:70 v/v ratio as the mobile phase at 1.0 mL/min flow rate and 0.50 ?L injection volume. The analytes were separated on a BEH C18 column (1.8?, 100×2.1mm) and detected at 265nm. Bictegravir, Emtricitabine and Tenofovir Alafenamide Fumarate obeyed Beer"s law in the ranges of 5?75 ?g/mL, 20-300 ?g/mL and 2.50?37.50 ?g/mL respectively. The recovery for accuracy was 99-101%. Precision and robustness met acceptable limits. This stability indicating method could distinguish and quantify the compounds even with degradants. Thus, a specific, accurate and robust stability indicating method was developed to simultaneously quantify Bictegravir, Emtricitabine and Tenofovir Alafenamide fumarate in their combined dosage form. Keywords : bictegravir, emtricitabine, tenofovir alafenamide fumarate, UPLC